Therapy Component Trips Up Lykos’ MDMA At US FDA AdComm For PTSD
Executive Summary
Functional unblinding and vague psychotherapy guidance lead to two negative votes for Lykos’ pioneering psychotherapy-assisted psychedelic therapy at the US FDA’s Psychopharmacologic Drugs Advisory Committee.